Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CCR8 | P51685 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781323 | 0.96 | CHRM4 (0.43) | CHRM4KCNH2CCR8 | |
| SCHEMBL5815483 | 0.88 | KCNH2 (0.42) | CHRM4KCNH2CCR8 | |
| Oxalic Acid SCHEMBL5780721 | 0.88 | KCNH2 (0.42) | KCNH2CCR8MEN1KMT2A | |
| Oxalic Acid SCHEMBL5781973 | 0.87 | EPHX2 (0.45) | CHRM4KCNH2 | |
| Oxalic Acid SCHEMBL5777380 | 0.87 | KCNH2 (0.41) | KCNH2CCR8MEN1KMT2A | |
| Oxalic Acid SCHEMBL6896125 | 0.87 | KCNH2 (0.41) | KCNH2CCR8MEN1KMT2A | |
| Oxalic Acid SCHEMBL5782385 | 0.87 | KDM4E (0.44) | MEN1KMT2A | |
| Oxalic Acid SCHEMBL5779827 | 0.87 | KCNH2 (0.47) | CHRM4KCNH2MEN1KMT2APOLB | |
| Oxalic Acid SCHEMBL6892216 | 0.87 | MEN1 (0.40) | KCNH2MEN1KMT2APOLB | |
| Oxalic Acid SCHEMBL5778676 | 0.86 | CHRM4 (0.44) | CHRM4MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | CHRM4 887/4885KCNH2 6/4885CCR8 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.